


## CBB1007

Cat. No.:	HY-15313
CAS No.:	1379573-92-8
Molecular Formula:	C <sub>27</sub> H <sub>34</sub> N <sub>8</sub> O <sub>4</sub>
Molecular Weight:	534.61
Target:	Histone Demethylase
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

### Description

CBB1007 is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC<sub>50</sub> = 5.27 μM for hLSD1). IC<sub>50</sub> Value: 5.27 uM Target: hLSD1 CBB1007 efficiently can block LSD1-mediated demethylation of H3K4Me<sub>2</sub> and H3K4Me (IC<sub>50</sub> ≤ 5 μM) with no effect on H3K4Me<sub>3</sub> and H3K9Me<sub>2</sub>, and LSD2 and JARID1A activities. Increases H3K4Me<sub>2</sub> and H3K4Me contents (IC<sub>50</sub> ≤ 5 μM), and causes activation of epigenetically suppressed CHRM4/M4-ArchR and SCN3A genes in F9 cells (IC<sub>50</sub> ≤ 3.74 μM). CBB1007 was Shown to preferentially arrest the growth of pluripotent tumors with minimal effect on non-pluripotent cancer or normal somatic cells (IC<sub>50</sub> ≥ 100 μM).

## REFERENCES

[1]. Wang J, et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 2011 Dec 1;71(23):7238-49.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA